Endo International Announces Federal Jury Rules In Co.’s Favor In Opana ER Antitrust Trial

 Endo International plc (NASDAQ:ENDP) announced today that a federal jury in Chicago, Illinois, has returned a verdict in favor of the Company's subsidiaries Endo Pharmaceuticals Inc. and Endo Health

 Endo International plc (NASDAQ:ENDP) announced today that a federal jury in Chicago, Illinois, has returned a verdict in favor of the Company’s subsidiaries Endo Pharmaceuticals Inc. and Endo Health Solutions Inc. (collectively Endo), in an antitrust trial.

As Endo previously disclosed, it has been involved since 2014 in various legal proceedings filed by multiple plaintiffs, including classes of direct and indirect purchasers, which have been consolidated in the United States District Court for the Northern District of Illinois under the caption In re Opana® ER Antitrust Litigation.  Plaintiffs in the cases alleged, among other things, that the terms of a 2010 patent settlement agreement between Endo and Impax Laboratories, Inc. (now Amneal Pharmaceuticals, Inc.) (Impax) violated the antitrust laws.  A trial of all plaintiffs’ claims began in June and concluded today with a verdict in favor of Endo on all counts.

“Endo is very pleased with the jury’s verdict and is grateful for its careful deliberation,” said Matthew J. Maletta, Endo’s Executive Vice President, Chief Legal Officer and Company Secretary. “Today’s verdict confirms that the 2010 settlement agreement between Endo and Impax was procompetitive and enabled Impax to come to market with its generic version of Opana® ER years earlier than otherwise would have been permitted.”   

Total
0
Shares
Related Posts